Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties - Université de Lille Accéder directement au contenu
Article Dans Une Revue British Journal of Pharmacology Année : 2020

Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties

Résumé

Intestinal mucositis refers to mucosal damage caused by cancer treatment, and irinotecan is one of the agents most associated with this condition. Focusing on the development of alternatives to prevent this important adverse effect, we evaluated the activity of the flavonoid luteolin, which has never been tested for this purpose despite its biological potential. The effects of luteolin were examined on irinotecan-induced intestinal mucositis in mice. Clinical signs were evaluated. Moreover, histological, oxidative, and inflammatory parameters were analysed, as well as the possible interference of luteolin in the anti-tumour activity of irinotecan. Luteolin (30 mg·kg-1 Luteolin prevents intestinal mucositis induced by irinotecan and therefore could be a potential adjunct in anti-tumour therapy to control this adverse effect, increasing treatment adherence and consequently the chances of cancer remission.
Fichier non déposé

Dates et versions

hal-04410610 , version 1 (22-01-2024)

Identifiants

Citer

Thaise Boeing, Priscila de Souza, Silvia Speca, Lincon Bordignon Somensi, Luisa Nathalia Bolda Mariano, et al.. Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties. British Journal of Pharmacology, 2020, British Journal of Pharmacology, 177 (10), pp.2393-2408. ⟨10.1111/bph.14987⟩. ⟨hal-04410610⟩

Collections

RIIP UNIV-LILLE
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More